Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Long-Term Investments (2016 - 2023)

Historic Long-Term Investments for Myriad Genetics (MYGN) over the last 14 years, with Q2 2023 value amounting to $6.2 million.

  • Myriad Genetics' Long-Term Investments fell 9210.19% to $6.2 million in Q2 2023 from the same period last year, while for Jun 2023 it was $6.2 million, marking a year-over-year decrease of 9210.19%. This contributed to the annual value of $54.8 million for FY2022, which is 711.86% down from last year.
  • As of Q2 2023, Myriad Genetics' Long-Term Investments stood at $6.2 million, which was down 9210.19% from $30.4 million recorded in Q1 2023.
  • In the past 5 years, Myriad Genetics' Long-Term Investments ranged from a high of $78.5 million in Q2 2022 and a low of $6.2 million during Q2 2023
  • Its 5-year average for Long-Term Investments is $42.8 million, with a median of $45.2 million in 2020.
  • Per our database at Business Quant, Myriad Genetics' Long-Term Investments surged by 49495.8% in 2022 and then tumbled by 9210.19% in 2023.
  • Quarter analysis of 5 years shows Myriad Genetics' Long-Term Investments stood at $47.6 million in 2019, then crashed by 55.88% to $21.0 million in 2020, then surged by 180.95% to $59.0 million in 2021, then decreased by 7.12% to $54.8 million in 2022, then tumbled by 88.69% to $6.2 million in 2023.
  • Its Long-Term Investments stands at $6.2 million for Q2 2023, versus $30.4 million for Q1 2023 and $54.8 million for Q4 2022.